Back

Peroxiredoxin-4 and beta-hydroxybutyrate after SGLT2 inhibitor treatment in heart failure with preserved ejection fraction

19 May 2025 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Diagnosis and prognosis of HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Miss Anouk Achten

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Frailty and cardiovascular comorbidities as predictors of short-term outcomes in HFpEF and HFmrEF patients: a retrospective cohort analysis
Associate Professor A. Briasoulis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Differences in heart failure with preserved ejection fraction diagnostic and therapeutic practices between physicians from europe and the middle east and north africa: an international survey
Professor H. Alarfaj (Riyadh, SA)
Abstract Slides Video
Presentation thumbnail
Incident atrial fibrillation in heart failure with preserved or reduced ejection fraction: the single centre experience
Assistant Professor M. Pandrc (Belgrade, RS)
Abstract Slides Video

Access the full session

Session thumbnail
Diagnosis and prognosis of HFpEF

The Event

Event poster

Heart Failure 2025

19 May 2025 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function
thumbnail
Congress Presentation
Effects of SGLT2i on CGA and biomarkers of oxidative stress and platelet activation in elderly diabetic patients with HFpEF.
thumbnail
Congress Session
The therapeutic conundrum in HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources